Home » Stocks » Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (ATNM)

Stock Price: $9.79 USD -0.12 (-1.21%)
Updated Aug 14, 2020 3:37 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 133.00M
Revenue (ttm) n/a
Net Income (ttm) -21.90M
Shares Out 13.59M
EPS (ttm) -4.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $9.79
Previous Close $9.91
Change ($) -0.12
Change (%) -1.21%
Day's Open 10.02
Day's Range 9.66 - 10.14
Day's Volume 279,232
52-Week Range 4.71 - 19.47

More Stats

Market Cap 133.00M
Enterprise Value 127.92M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 13.59M
Float 13.00M
EPS (basic) -3.9
EPS (diluted) -4.03
FCF / Share -3.79
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 451,384
Short Ratio 0.66
Short % of Float 3.43%
Beta 1.80
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 42.96
Revenue n/a
Operating Income -22.06M
Net Income -21.90M
Free Cash Flow -21.84M
Net Cash 5.08M
Net Cash / Share 0.37
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -133.84%
ROE -523.73%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(589.48% upside)
Current: $9.79
Target: 67.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-22.07-23.83-26.91-26.85-24.83-22.48-6.59-7.95-3.28
Net Income-21.90-23.65-26.60-24.32-21.03-24.69-10.77-8.36-3.44
Shares Outstanding4.983.532.221.621.270.910.760.040.03
Earnings Per Share-4.50-6.60-12.00-15.00-16.50-27.00-14.10-227.40-129.00
Operating Cash Flow-21.46-20.57-21.55-20.79-18.54-14.35-6.29-5.21-0.52
Capital Expenditures-0.06-0.10-0.02-0.06-0.05-0.15-0.02--
Free Cash Flow-21.53-20.67-21.58-20.85-18.59-14.50-6.31-5.22-0.52
Cash & Equivalents9.6914.1017.7920.5525.686.745.535.625.70
Total Debt1.430.26--
Net Cash / Debt8.2713.8417.7920.5525.416.465.385.485.58
Book Value5.648.8113.6718.0121.97-1.92-1.561.150.99
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Actinium Pharmaceuticals, Inc.
Country United States
CEO Sandesh Seth

Stock Information

Ticker Symbol ATNM
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: ATNM


Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.